key: cord-0942338-hjucs9cx
authors: Stanley, Kelly; Hanmod, Santosh; Simpson, Richard J; Katsanis, Emmanuel
title: Haploidentical hematopoietic cell transplantation is even more advantageous during the COVID‐19 pandemic
date: 2021-03-17
journal: Pediatr Transplant
DOI: 10.1111/petr.14004
sha: 5f248010af34afb400f5d5766eea3e17826dc5e8
doc_id: 942338
cord_uid: hjucs9cx

nan

To the Editor

The SARS-CoV-2 has overwhelmed healthcare systems worldwide.

Hematopoietic cell transplantation (HCT) has been uniquely affected as this virus may not only severely impact the immunocompromised recipient but also the potential stem cell donor. 1 

The challenge of COVID-19 and hematopoietic cell transplantation; EBMT recommendations for management of hematopoietic cell transplant recipients, their donors, and patients undergoing CAR T-cell therapy

Clinical characteristics and outcomes of COVID-19 in haematopoietic stem-cell transplantation recipients: an observational cohort study

Potential niche indications for blinatumomab as a bridge to hematopoietic cell transplantation

T-Cell replete myeloablative haploidentical bone marrow transplantation is an effective option for pediatric and young adult patients with high-risk hematologic malignancies

Haploidentical bone marrow transplantation with post-transplant cyclophosphamide/ bendamustine in pediatric and young adult patients with hematologic malignancies